Citius Oncology Reports $1.49 Million Revenue in Q3 2026, Net Loss of $8.92 Million

Citius Oncology, Inc. reported its financial results for the third quarter of fiscal year 2026, revealing a revenue of $1.49 million for the three months ended June 30, 2026, compared to no revenue in the same period last year. For the nine months ended June 30, 2026, the company generated $7.11 million in revenue, marking a significant milestone since the commercial launch of its oncology immunotherapy product, LYMPHIR, in December 2025. The gross profit for the quarter was approximately 67%, while the gross profit for the nine-month period was about 77%. Despite these revenue figures, Citius Oncology reported a net loss of $8.92 million for the quarter and $41.07 million for the nine months, reflecting an increase in operating expenses primarily due to the expansion of its commercial organization and amortization of in-process research and development.

The company's total operating expenses for the three months ended June 30, 2026, were $9.72 million, up from $4.94 million in the same quarter of the previous year. This increase was largely attributed to higher general and administrative expenses, which rose to $4.22 million from $1.88 million, and stock-based compensation expenses, which increased to $3.56 million from $2.13 million. For the nine-month period, total operating expenses reached $48.08 million, compared to $18.81 million in the prior year, driven by significant costs associated with the commercial launch of LYMPHIR and a contract cancellation fee of approximately $19.73 million related to a terminated manufacturing agreement.

Citius Oncology's balance sheet as of June 30, 2026, showed total assets of $112.09 million, up from $100.94 million at the end of the previous fiscal year. The company had cash and cash equivalents of $16.56 million, a substantial increase from $3.92 million as of September 30, 2025. However, the company also reported total liabilities of $71.71 million, which included a significant increase in accrued expenses and accounts payable. The company’s accumulated deficit reached $105.11 million, reflecting its ongoing investment in research and development and commercialization efforts.

Strategically, Citius Oncology has made significant strides in expanding its commercial operations. The company reported that 44 institutions have ordered LYMPHIR since its launch, with a notable increase in orders and institutional uptake. The company has also initiated shipments to Europe through a regional distribution partner, marking its first step in international expansion. Additionally, Citius Oncology has expanded its commercial organization by adding 21 field-based professionals and eight medical science liaisons to enhance its engagement with healthcare providers.

Looking ahead, Citius Oncology anticipates continued revenue growth as LYMPHIR gains market acceptance. The company plans to rely on funding from its parent company, Citius Pharmaceuticals, as well as additional capital raises to support its operations. However, there is substantial doubt about the company's ability to continue as a going concern beyond November 2026 without securing further financing. The company has retained Jefferies LLC as its financial advisor to explore strategic alternatives aimed at maximizing shareholder value.